Esperion Logo (primary).png
Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
13. Oktober 2016 07:30 ET | Esperion Therapeutics, Inc.
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and...
Esperion Logo (primary).png
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
12. Januar 2016 16:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...